Match!

Links between Pharmaceutical R&D Models and Access to Affordable Medicines

Published on Oct 31, 2016
Brian Godman41
Estimated H-index: 41
(Strathclyde Institute of Pharmacy and Biomedical Sciences),
Wija Oortwijn11
Estimated H-index: 11
+ 5 AuthorsJeroen van der Tuin2
Estimated H-index: 2
Abstract
Each patient in the European Union has a right of access to care. National governments face the challenge to balance resources against healthcare demand to ensure that populations enjoy equitable access to effective, affordable and sustainable healthcare. This study describes the main challenges with regard to access to affordable medicines, including Research & Development, pricing and reimbursement of medicines and the influence of the economic crisis. Potential policy options to tackle these challenges are presented, drawing on best practices and a review of specific measures implemented in different European countries. This document was provided by Policy Department A for the Committee on the Environment, Public Health and Food Safety.
  • References (0)
  • Citations (3)
📖 Papers frequently viewed together
4 Citations
2 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References0
Newest
Cited By3
Newest
#1Brian Godman (Strathclyde Institute of Pharmacy and Biomedical Sciences)H-Index: 41
#2Mainul Haque (National Defence University of Malaysia)H-Index: 11
Last. Ruaraidh Hill (University of Liverpool)H-Index: 14
view all 37 authors...
AbstractIntroduction: Antibiotics are indispensable to maintaining human health; however, their overuse has resulted in resistant organisms, increasing morbidity, mortality and costs. Increasing an...
7 CitationsSource
#1André Soares Santos (UFMG: Universidade Federal de Minas Gerais)H-Index: 2
#2AA Guerra-Júnior (UFMG: Universidade Federal de Minas Gerais)H-Index: 2
Last. Cristina Mariano Ruas Brandão (UFMG: Universidade Federal de Minas Gerais)H-Index: 8
view all 5 authors...
Abstract Background Only a small share of new drugs is truly innovative; 85% to 90% of all new health technologies have little or no advantage over existing therapeutic alternatives. Health economic evaluations can be used to induce acceptable prices for new technologies through threshold pricing. Objective This work discusses a cost-effectiveness threshold (λ) to be applied to the price regulation of substitute technologies. Methods Considering that substitute technologies add only small margin...
Source
#1Wija Oortwijn (Ecorys)H-Index: 12
#2Domino Determann (Ecorys)H-Index: 1
Last. Jeroen van der Tuin (Ecorys)H-Index: 2
view all 5 authors...
Abstract Objectives To assess the level of comprehensiveness of health technology assessment (HTA) practices around the globe and to formulate recommendations for enhancing legitimacy and fairness of related decision-making processes. Methods To identify best practices, we developed an evaluation framework consisting of 13 criteria on the basis of the INTEGRATE-HTA model (integrative perspective on assessing health technologies) and the Accountability for Reasonableness framework (deliberative a...
8 CitationsSource